Clinical Update - PSD502

12 Jul 2007 07:01

Plethora Solutions Holdings PLC12 July 2007 Clinical Update - PSD502: First-line Therapy for Premature Ejaculation * Confirms PSD502 is well-tolerated * Rapid onset of action with 2 hour benefit * No unexpected adverse events; negligible systemic toxicity Plethora Solutions Holdings PLC ("Plethora" or the "Company", AIM : PLE), thespecialist urology company, provides an update on results from a recentlycompleted US Clinical study with PSD502. Following the granting of an IND earlier in the year, this clinical study hasbeen completed to determine the safety and tolerance of repeated dosing ofPSD502, and the local and systemic drug exposure and pharmacokinetics of theproduct. PSD502 (12 subjects) or placebo (four subjects) was dosed to healthymale volunteers at least once a day for 21 days, and three times daily on threeof these days. The trial results confirmed that PSD502 was well tolerated. The data alsoconfirm that the onset of action is within minutes (